Pathogenomix
Is this your brand? Claim it — free, and takes a minute with your work email.
Overview
Tagline Brand's website · 2026-10-04
Reduces pathogen identification time by up to 90%, provides answers where other methods fail, platform agnostic (Sanger, Targeted NGS, Long Reads) using novel algorithms, significantly reduces upload data volume (1000:1), utilizes automatically curated databases, offers bulk analysis with automatic confidence flags and report generation, can analyze complex/mixed samples, and Patho-Seq holds FDA Breakthrough Device Designation.
Description Brand's website · 2026-10-04
Pathogenomix provides Ripseq, a cloud-based software that converts sequencing files (Sanger, Targeted NGS, Long Reads) into clear, actionable pathogen reports. It drastically reduces identification time for infectious pathogens in pure and poly-microbial samples using novel algorithms and curated databases. Its Patho-Seq product has received FDA Breakthrough Device Designation.
Offerings
Core capabilities Brand's website · 2026-10-04
- Ripseq sequence-based analysis software (Ripseq NGS
- Ripseq Sanger)
- Ripseq DB (curated microbial reference database)
- Patho-Seq
Pricing Brand's website · 2026-10-04
Subscription-based with a 14-day free trial
Audience
Target industry Brand's website · 2026-10-04
Leading research institutions, hospitals, diagnostic laboratories worldwide (e.g., Mayo Clinic, ARUP Laboratories, Haukeland University Hospital, VA Healthcare)
Is this your business?
The information above is publicly sourced — assembled by Optimly from Pathogenomix's website and public pages.
Claim this profile to publish your own verified Business Profile and speak for Pathogenomix across the index.
Claim Pathogenomix — free →Page last updated 2026-10-17.